Key points are not available for this paper at this time.
Tuberculosis (TB) is the leading cause of death among persons with HIV. In 2022, an estimated 167, 000 TB-related deaths occurred globally among persons with HIV. TB preventive treatment (TPT) helps prevent TB disease and is recommended for persons at high risk for developing TB, including those with HIV. TPT, when taken with antiretroviral treatment (ART), can reduce TB-attributable deaths among persons with HIV. In 2018, the U. S. President's Emergency Plan for AIDS Relief (PEPFAR) program committed to offer one course of TPT to all eligible clients receiving ART. This analysis describes trends in TPT initiation and completion among PEPFAR-supported programs in 36 countries in Africa, Central and South America, and Asia during fiscal years (FYs) 2017-2023. Overall, TPT initiation rates peaked in FY19, a possible sign of programmatic saturation. TPT initiation among clients who had been on ART <6 months reached 59%, and overall completion rates up to 87% were reported. Approximately 13 million persons with HIV have completed TPT since FY17, but widespread adoption of shorter regimens, patient-centered approaches, and electronic medical record systems might be needed to ensure full TPT coverage. Through PEPFAR's partnership with national HIV programs, TPT has become the standard of care for persons with HIV. † https: //www. cdc. gov/globalhivtb/who-we-are/success-stories/success-storypages/scaling-tpt-ethiopia. html§ https: //www. who. int/publications/m/item/political-declaration-of-the-ungeneral-assembly-high-level-meeting-on-the-fight-against-tuberculosis¶ https: //na. usembassy. gov/wp-content/uploads/sites/132/PEPFAR-COP18-GuidanceFINAL-1.
Ajiboye et al. (Thu,) studied this question.